Moleculin Stockholders Approve Reverse Split Authority and 3.86M Share Plan Expansion
MBRX has more than doubled off its 52-week low of $0.161 on light trading volume (0.3× avg).
Summary
Moleculin stockholders approved reverse split authority and a 3.86 million share equity plan expansion, while rejecting a proposal to eliminate supermajority voting requirements.
Key Events · Corporate Governance and Compliance · MBRX
-
Reverse Split Authority Approved
Stockholders approved granting the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20, valid for one year. This is the primary mechanism to regain Nasdaq minimum bid compliance after the September 15, 2026 delisting notice.
-
Equity Plan Expanded by 3.86M Shares
The 2024 Stock Plan was amended to increase authorized shares by 3,861,894 to 3,875,999 total. Against 19,477,380 shares outstanding, this represents roughly 20% potential additional dilution.
-
Supermajority Elimination Rejected
Proposal 5 to eliminate supermajority voting requirements for charter amendments failed, receiving 2,828,497 votes for versus 901,488 against — short of the required two-thirds of outstanding shares.
-
Directors and Auditor Ratified
All five director nominees were elected, and Grant Thornton LLP was ratified as independent auditor for fiscal 2026 with 7,592,200 votes for.
Analysis · MBRX · Life Sciences
Moleculin's annual meeting delivered two critical governance approvals: authority for a reverse stock split (1-for-2 to 1-for-20) and a 3.86 million share expansion of its equity plan. The reverse split authority is the company's primary tool to regain Nasdaq minimum bid compliance after the September 15 delisting notice. The equity plan expansion adds roughly 20% to the current 19.5 million shares outstanding, creating meaningful potential dilution for existing holders. Notably, stockholders rejected the proposal to eliminate supermajority voting requirements, preserving a higher bar for future charter amendments.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.2% of the 1631 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.16 to $15.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.